We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.24%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$10.8B
AUM Growth
-$577M
Cap. Flow
-$347M
Cap. Flow %
-3.21%
Top 10 Hldgs %
77.46%
Holding
139
New
12
Increased
27
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$517M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$232M
3
DBVT
DBV Technologies
DBVT
+$142M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$66.6M
5
NGNE icon
Neurogene
NGNE
+$63.9M

Top Sells

Rank Stock Value
1
XOMA
Xoma
XOMA
+$57M
2
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$29.2M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.1M
4
OMER icon
Omeros
OMER
+$9.78M
5
DYAX
DYAX CORPORATION
DYAX
+$8.72M

Sector Composition

Rank Sector Weight
1 Healthcare 77.98%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
101
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.44M 0.01%
35,649
– –
CLLS
102
Cellectis
CLLS
$342M
$1.32M 0.01%
50,000
– –
TENX icon
103
Tenax Therapeutics
TENX
$65.5M
$1.26M 0.01%
13
+2
+18% +$229K
ADAP
104
DELISTED
Adaptimmune Therapeutics
ADAP
$1.2M 0.01%
100,000
– –
BDSI
105
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.17M 0.01%
210,021
– –
ABUS icon
106
Arbutus Biopharma
ABUS
$1.03B
$1.1M 0.01%
180,582
– –
WINT
107
DELISTED
Windtree Therapeutics Inc
WINT
$1.07M 0.01%
254,975
– –
NBSE
108
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.02M 0.01%
926
– –
ALNY icon
109
Alnylam Pharmaceuticals
ALNY
$31.6B
$911K 0.01%
11,340
– –
ALDX icon
110
Aldeyra Therapeutics
ALDX
$91.7M
$828K 0.01%
142,000
– –
TRIL
111
DELISTED
Trillium Therapeutics Inc.
TRIL
$821K 0.01%
+63,014
New +$1.16M
AIXC
112
AIxCrypto Holdings Inc
AIXC
$22.7M
$820K 0.01%
3
– –
XLRN
113
DELISTED
Acceleron Pharma
XLRN
$716K 0.01%
28,765
– –
QURE icon
114
uniQure
QURE
$3.36B
$614K 0.01%
30,000
– –
AKAO
115
DELISTED
Achaogen Inc
AKAO
$576K 0.01%
100,000
– –
FMI
116
DELISTED
Foundation Medicine, Inc.
FMI
$385K ﹤0.01%
20,892
– –
SGYP
117
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$356K ﹤0.01%
+67,100
New +$519K
CCXI
118
DELISTED
ChemoCentryx, Inc.
CCXI
$297K ﹤0.01%
49,064
– –
FPRX
119
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$296K ﹤0.01%
19,247
– –
APTO
120
DELISTED
Aptose Biosciences, Inc.
APTO
$144K ﹤0.01%
74
– –
BTX.WS
121
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$17K ﹤0.01%
20,084
– –
TCRT icon
122
Alaunos Therapeutics
TCRT
$4.47M
– –
-1,262
Closed -$2.27M
VNDA icon
123
Vanda Pharmaceuticals
VNDA
$319M
– –
-409,881
Closed -$5.2M
VXRT
124
DELISTED
Vaxart
VXRT
– –
-75,495
Closed -$1.72M
XOMA
125
DELISTED
Xoma
XOMA
– –
-734,176
Closed -$57M
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2015 Portfolio in Review

As of Q3 2015, Julian Baker held 139 positions worth $10.8B, down 5.1% from $11.4B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker withdrew a net $347M in Q3 2015, closing 6 positions and reducing 8 holdings. Its most notable exit was Xoma, an estimated $57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in MEDIVATION, INC. worth $28M.

  • Julian Baker's largest Q3 2015 buy was MEDIVATION, INC.: 659,752 shares worth $28M.
  • Julian Baker added most to Incyte in Q3 2015, an estimated $517M increase.
  • Julian Baker's biggest Q3 2015 reduction was Alder Biopharmaceuticals, cutting an estimated $16.1M.
  • Julian Baker fully exited Xoma in Q3 2015, selling an estimated $57M.
  • Julian Baker's ten largest holdings make up 77% of its $10.8B portfolio in Q3 2015.
  • Julian Baker opened 12 new positions and closed 6 in Q3 2015.
  • Julian Baker's portfolio value fell 5.1% quarter-over-quarter to $10.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.